Nabriva Therapeutics PLC (NBRV)
0.7075
-0.03 -4.13%
NASDAQ
Dec 3, 16:00
0.7075
0.00 0.00%
After-Hours: 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 20.34M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.14 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -54.22M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 50.13% |
| Profit Margin (Quarterly) | -126.5% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 40.13M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 1.162 |
| PE Ratio | -- |
| Price to Book Value | 0.6341 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.1256 |
| Free Cash Flow (Quarterly) | -13.24M |
| Return on Equity | Upgrade |
View All NBRV News
News
-
WireHeadlineTime (ET)
-
MT Newswires11/29 10:29
-
Yahoo11/29 09:00
-
Yahoo11/24 10:00
-
Yahoo11/18 06:23
-
Globe Newswire11/11 07:01
-
MT Newswires11/09 16:10
-
MT Newswires11/09 16:10
-
Yahoo11/09 16:01
-
Globe Newswire11/09 16:01
-
Globe Newswire11/05 07:01
-
Globe Newswire11/01 07:01
-
Yahoo10/26 07:01
-
Globe Newswire10/15 16:05
-
Yahoo10/05 08:01
-
Globe Newswire10/04 16:05
-
Globe Newswire10/01 16:05
-
Yahoo10/01 12:35
-
Globe Newswire10/01 07:01
-
PR Newswire09/30 08:00
-
Globe Newswire09/24 07:01
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 03/11/2022 | Earnings Results | Q4 2021 Earnings Results |
| 03/11/2022 16:30 EST | Earnings Calls | Q4 2021 Earnings Call |
| 11/09/2021 | Earnings Results | Q3 2021 Earnings Results |
| 11/09/2021 16:30 EST | Earnings Calls | Q3 2021 Earnings Call |
| 08/05/2021 | Earnings Results | Q2 2021 Earnings Results |
| 08/05/2021 16:30 EST | Earnings Calls | Q2 2021 Earnings Call |
| 07/28/2021 12:00 EST | AGM | 2021 Annual General Meeting |
| 05/06/2021 | Earnings Results | Q1 2021 Earnings Results |
| 05/06/2021 16:30 EST | Earnings Calls | Q1 2021 Earnings Call |
| 03/11/2021 | Earnings Results | Q4 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
- URL: http://www.nabriva.com
- Investor Relations URL: N/A
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: Mar. 11, 2022
- Last Earnings Release: Nov. 09, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 0.7075 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- NBRV Tweets Stocktwits
Advertisement
